163 related articles for article (PubMed ID: 28220831)
1. The distribution of the apparent diffusion coefficient as an indicator of the response to chemotherapeutics in ovarian tumour xenografts.
Tourell MC; Shokoohmand A; Landgraf M; Holzapfel NP; Poh PS; Loessner D; Momot KI
Sci Rep; 2017 Feb; 7():42905. PubMed ID: 28220831
[TBL] [Abstract][Full Text] [Related]
2. Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects.
Sala E; Kataoka MY; Priest AN; Gill AB; McLean MA; Joubert I; Graves MJ; Crawford RA; Jimenez-Linan M; Earl HM; Hodgkin C; Griffiths JR; Lomas DJ; Brenton JD
Radiology; 2012 Apr; 263(1):149-59. PubMed ID: 22332064
[TBL] [Abstract][Full Text] [Related]
3. Combretastatin A-1 phosphate potentiates the antitumor activity of carboplatin and paclitaxel in a severe combined immunodeficiency disease (SCID) mouse model of human ovarian carcinoma.
Staflin K; Järnum S; Hua J; Honeth G; Kannisto P; Lindvall M
Int J Gynecol Cancer; 2006; 16(4):1557-64. PubMed ID: 16884365
[TBL] [Abstract][Full Text] [Related]
4. Relationship between chemotherapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and expression of proliferation markers and tumour suppressor gene p53 in human ovarian cancer xenografts in nude mice.
Kolberg HC; Villena-Heinsen C; Deml MM; Kraemer S; Diedrich K; Friedrich M
Eur J Gynaecol Oncol; 2005; 26(4):398-402. PubMed ID: 16122187
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.
Moisan F; Francisco EB; Brozovic A; Duran GE; Wang YC; Chaturvedi S; Seetharam S; Snyder LA; Doshi P; Sikic BI
Mol Oncol; 2014 Oct; 8(7):1231-9. PubMed ID: 24816187
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer.
Koussounadis A; Langdon SP; Harrison DJ; Smith VA
Br J Cancer; 2014 Jun; 110(12):2975-84. PubMed ID: 24867692
[TBL] [Abstract][Full Text] [Related]
7. Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues.
Jarvis IW; Meczes EL; Thomas HD; Edmondson RJ; Veal GJ; Boddy AV; Ottley CJ; Pearson DG; Tilby MJ
Biochem Pharmacol; 2012 Jan; 83(1):69-77. PubMed ID: 22015635
[TBL] [Abstract][Full Text] [Related]
8. Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan.
Nakamura Y; Kamei T; Shinagawa M; Sakamoto Y; Miwa I
J Obstet Gynaecol Res; 2015 May; 41(5):809-12. PubMed ID: 25511544
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
Joerger M; Huitema AD; Richel DJ; Dittrich C; Pavlidis N; Briasoulis E; Vermorken JB; Strocchi E; Martoni A; Sorio R; Sleeboom HP; Izquierdo MA; Jodrell DI; Calvert H; Boddy AV; Hollema H; Féty R; Van der Vijgh WJ; Hempel G; Chatelut E; Karlsson M; Wilkins J; Tranchand B; Schrijvers AH; Twelves C; Beijnen JH; Schellens JH
Clin Cancer Res; 2007 Nov; 13(21):6410-8. PubMed ID: 17975154
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion-weighted imaging.
Canese R; Pisanu ME; Mezzanzanica D; Ricci A; Paris L; Bagnoli M; Valeri B; Spada M; Venditti M; Cesolini A; Rodomonte A; Giannini M; Canevari S; Podo F; Iorio E
NMR Biomed; 2012 Apr; 25(4):632-42. PubMed ID: 22020805
[TBL] [Abstract][Full Text] [Related]
11. Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells.
Kramer D; Stark N; Schulz-Heddergott R; Erytch N; Edmunds S; Roßmann L; Bastians H; Concin N; Moll UM; Dobbelstein M
Cell Death Differ; 2017 Feb; 24(2):300-316. PubMed ID: 27834954
[TBL] [Abstract][Full Text] [Related]
12. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
[TBL] [Abstract][Full Text] [Related]
13. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.
Weigel MT; Rath K; Alkatout I; Wenners AS; Schem C; Maass N; Jonat W; Mundhenke C
Oncology; 2014; 87(4):232-45. PubMed ID: 25116401
[TBL] [Abstract][Full Text] [Related]
15. Value of diffusion-weighted imaging for assessing site-specific response of advanced ovarian cancer to neoadjuvant chemotherapy: correlation of apparent diffusion coefficients with epithelial and stromal densities on histology.
Kyriazi S; Nye E; Stamp G; Collins DJ; Kaye SB; deSouza NM
Cancer Biomark; 2010; 7(4):201-10. PubMed ID: 21576813
[TBL] [Abstract][Full Text] [Related]
16. A bioengineered 3D ovarian cancer model for the assessment of peptidase-mediated enhancement of spheroid growth and intraperitoneal spread.
Loessner D; Rizzi SC; Stok KS; Fuehrmann T; Hollier B; Magdolen V; Hutmacher DW; Clements JA
Biomaterials; 2013 Oct; 34(30):7389-400. PubMed ID: 23827191
[TBL] [Abstract][Full Text] [Related]
17. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
18. Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopy.
Zhai G; Kim H; Sarver D; Samuel S; Whitworth L; Umphrey H; Oelschlager DK; Beasley TM; Zinn KR
J Magn Reson Imaging; 2014 Jun; 39(6):1588-94. PubMed ID: 24151215
[TBL] [Abstract][Full Text] [Related]
19. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy.
Press JZ; Kenyon JA; Xue H; Miller MA; De Luca A; Miller DM; Huntsman DG; Gilks CB; McAlpine JN; Wang YZ
Gynecol Oncol; 2008 Aug; 110(2):256-64. PubMed ID: 18547621
[TBL] [Abstract][Full Text] [Related]
20. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.
Winterhoff B; Freyer L; Hammond E; Giri S; Mondal S; Roy D; Teoman A; Mullany SA; Hoffmann R; von Bismarck A; Chien J; Block MS; Millward M; Bampton D; Dredge K; Shridhar V
Eur J Cancer; 2015 May; 51(7):879-892. PubMed ID: 25754234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
